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Breast cancer encompasses a plethora of distinct diseases 
characterised by diﬀ erent biological features and clinical 
outcomes [1-3]. Microarray-based gene expression proﬁ l-
ing studies have played a pivotal role in unravelling the 
molecular and clinical diversity of the disease (for a 
review see [3]). Th ese studies led to the development of a 
molecular classiﬁ cation of breast cancer [4], where the 
diﬀ erent molecular subtypes identiﬁ ed were found to be 
associated with distinct clinical outcomes [5,6], and to 
the development of numerous multigene predictors (that 
is, gene signatures) of outcome, which were initially 
reported to outperform the current clinicopathological 
algorithms to deﬁ ne the prognosis of breast cancer 
patients [7,8] (reviewed in [3,9]).
Microarrays have also played a pivotal role in 
addressing one of the major bottlenecks in translational 
research: ascribing relevance in the human disease 
context of results obtained from in vitro studies and 
animal models. Th e availability of multiple gene expres-
sion datasets with patient follow-up in the public domain 
allowed the investigation of whether a microarray-based 
signature derived from a set of laboratory experiments 
would have biological signiﬁ cance. For instance, a 
signature derived from tumour-initiating breast cancer 
cells was shown to be of prognostic signiﬁ cance in a 
publicly available microarray dataset, and this was used 
as the basis to suggest that the tumourigenic breast 
cancer cell signature ‘may detect transcriptional proﬁ les 
associated with mutations that arrest cells in an immature 
state of diﬀ erentiation and function as markers of more 
aggressive tumors’ [10].
In their recent paper [11], Venet and colleagues made 
the intriguing observation that gene signatures developed 
to identify phenomena completely unrelated to cancer – 
such as the eﬀ ect of postprandial laughter on peripheral 
blood mononuclear cells, the localisation of skin ﬁ bro-
blasts or social defeat obtained from mice brains – were 
signiﬁ cantly associated with outcome in a cohort of 295 
breast cancer patients of the Netherlands Cancer Insti-
tute (NKI-295) [8]. In addition, it was also shown that, 
out of 1,890 gene signatures deposited in the Molecular 
Signatures Database, 67% were associated with breast 
cancer outcome at P  <0.05, and 23% were associated at 
P  <10−5. Th e large number of signatures signiﬁ cantly 
associated with outcome may be due to the enrichment 
of the Molecular Signatures Database with cancer-related 
signatures; hence the authors generated for each 
Molecular Signa tures Database signature a signature of 
identical size but composed of randomly selected genes. 
Strikingly, out of these randomly derived signatures, 77% 
were associated with outcome at P  <0.05 and 30% were 
associated at P <10−5. Furthermore, the authors went on 
to show that only 18 of the 47 published prognostic 
signatures that were either derived for the purpose of 
ﬁ nding better prognostic tools or, in most cases, were 
used to suggest biological relevance of laboratory ﬁ ndings 
performed statistically better than the best 5% of random 
gene signatures of the same size [11].
A critically relevant set of observations made by Venet 
and colleagues include the fact that >90% of randomly 
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Testing the statistical associations between microarray-
based gene expression signatures and patient outcome 
has become a popular approach to infer biological 
and clinical signifi cance of laboratory observations. 
Venet and colleagues recently demonstrated that 
the majority of randomly generated gene signatures 
are signifi cantly associated with outcome of breast 
cancer patients, and that this association stems from 
the fact that a large proportion of the transcriptome 
is signifi cantly correlated with proliferation, a strong 
predictor of outcome in breast cancer patients. These 
fi ndings demonstrate that a statistical association 
between a gene signature and disease outcome does 
not necessarily imply biological signifi cance.
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generated signatures containing >100 genes were shown 
to be associated with outcome of breast cancer patients 
[11]. Further, up to 26% of all probes within the micro-
array platform used for the analysis of the samples from 
the NKI-295 dataset were signiﬁ cantly associated with 
outcome on univariate analysis. Even when more strin-
gent parameters (that is, the q value) to account for the 
false discovery stemming from multiple comparisons 
were used, 17% of all probe sets were shown to be signi ﬁ -
cantly associated with outcome [11]. What are the statis-
tical and/or biological reasons for these observations?
Given that previous studies had revealed that prolifera-
tion is the main and shared determinant of the prognostic 
accuracy of multigene predictors of outcome in breast 
cancer patients [3,12-14], the authors developed a proli-
fera tion metagene called meta-PCNA. Th is metagene 
was composed of the top 1% of genes whose expression 
was most positively correlated with the expression of the 
proliferating cell nuclear antigen (PCNA) across 36 
normal tissues. Venet and colleagues conﬁ rmed that 
proliferation is a major prognostic determinant of 
outcome in unstratiﬁ ed breast cancer patients [11]. meta-
PCNA was then used to adjust the expression data of 
breast cancer gene signatures, which resulted in a 
dramatic reduction in the association between most pub-
lished and random signatures and outcome.
So why do random gene signatures with >100 genes 
correlate with breast cancer patient outcome? Th e crux 
of the problem appears to be the large number of 
proliferation-related genes in the breast cancer 
transcriptome itself, given that the authors found that 
58% of the microarray probes used for the analysis of the 
NKI-295 dataset were correlated with meta-PCNA [11]. 
Virtually any large collection of genes will therefore 
inevitably be enriched for proliferation-related genes. 
Moreover, given that there are many genes whose 
expression levels correlate with cell cycle and/or 
proliferation but whose main biological functions/gene 
ontology may not be related to these phenomena, any 
attempt to remove known proliferation-related genes as 
deﬁ ned by gene ontology are likely to be futile [11]. While 
this does not imply that the published signatures do not 
have prognostic value, the underlying unifying feature 
among them is the eﬀ ect of proliferation and the signal of 
additional biological relevance beyond this is minimal.
Arguably, one of the major contributions of Venet and 
colleagues was to bring to the attention of the breast 
cancer research community the limitations of an 
approach ever so familiar in this day and age: using 
micro arrays to suggest that a mechanism is relevant to 
human breast cancer from the ﬁ nding that a gene 
expression marker for this mechanism predicts outcome 
of breast cancer patients [11]. Th eir study has also 
reminded us of the old maxim that ‘correlation does not 
imply causation’. Th e assessment of the expression levels 
of a gene or gene signature may be clinically useful 
without yielding interesting biological or mechanistic 
insights. On the other hand, an association between a 
gene signature derived from laboratory experiments and 
the prognosis of breast cancer patients does not 
necessarily imply that the genes which compose a given 
signature are of biological signiﬁ cance to the disease.
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